ADMA Biologics (ADMA) director receives new RSU and option grants

Rhea-AI Filing Summary

ADMA Biologics director Eduardo Rene Salas reported new equity awards. On February 9, 2026, he acquired 10,690 shares of common stock in the form of restricted stock units, granted at a price of $0, which will vest in two equal installments over one year.

Following this grant, he beneficially owned 21,579 shares of common stock, including previously granted RSUs and 5,444 owned shares. He was also granted stock options to buy 17,730 shares of common stock at an exercise price of $16.37, vesting in twelve equal monthly installments and becoming fully vested one year from the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Salas Eduardo Rene

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,730	$0.00	--
Grant/Award	Common Stock	10,690	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 17,730 shares (Direct); Common Stock — 21,579 shares (Direct)

Footnotes (1)

1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 5,444 shares of common stock owned by the Reporting Person. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salas Eduardo Rene

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		10,690(1)	A	$0	21,579(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.37	02/09/2026		A		17,730		(3)	02/09/2036	Common Stock	17,730	$0	17,730	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 5,444 shares of common stock owned by the Reporting Person.

3. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

	/s/ Eduardo Rene Salas, by Michael A. Goldstein as attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADMA (ADMA) director Eduardo Rene Salas report?

Director Eduardo Rene Salas reported receiving equity awards, not an open-market trade. He was granted 10,690 restricted stock units and stock options for 17,730 shares, both at a grant price of $0, as part of his compensation package.

How many restricted stock units did the ADMA (ADMA) director receive?

He received 10,690 restricted stock units. These RSUs vest in two equal installments on the six- and twelve-month anniversaries of the February 9, 2026 grant date, becoming fully vested after one year if he continues serving the company.

What stock options were granted to the ADMA (ADMA) director in this Form 4?

He was granted stock options to buy 17,730 shares of ADMA Biologics common stock at an exercise price of $16.37 per share. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the grant date.

Did the ADMA (ADMA) director buy or sell shares in the market?

No market purchase or sale occurred. The filing shows a grant, classified as an acquisition under a compensation award. Both the 10,690 RSUs and 17,730 stock options were received at a grant price of $0, rather than through open-market trading.

How many ADMA (ADMA) shares does the director beneficially own after the grant?

After the reported transaction, he beneficially owned 21,579 shares of common stock. This total includes newly granted RSUs, previously granted RSUs scheduled to vest in 2026, and 5,444 shares of common stock already owned by the reporting person.

What are the vesting conditions for the ADMA (ADMA) director’s equity awards?

The 10,690 RSUs vest in two equal parts at six and twelve months, fully vesting by February 9, 2027. The 17,730 stock options vest monthly over one year, with all vesting contingent on the director’s continued service to the company.